endoribonucleaseprepar
sirna
esirna
altern
tool
chemic
synthet
sirna
gene
silenc
sinc
esirna
direct
long
target
sequenc
genet
variat
target
sequenc
littl
influenc
effect
abil
esirna
inhibit
hepat
b
viru
hbv
gene
express
replic
test
esirna
target
code
region
hbv
surfac
antigen
hbsag
nucleocapsid
hbcag
inhibit
specif
express
hbsag
hbcag
cotransfect
respect
express
plasmid
esirna
reduc
hbv
transcript
replic
intermedi
transient
transfect
cell
cell
hbv
genom
integr
stabli
compar
synthet
sirna
esirna
target
hbsag
less
effect
select
synthet
sirna
term
inhibit
hbv
gene
express
replic
howev
abil
synthet
sirna
specif
gene
silenc
impair
strongli
nucleotid
substitut
within
target
sequenc
effici
gene
silenc
esirna
influenc
sequenc
variat
transfect
esirna
induc
interferonstimul
gene
isg
like
indic
absenc
offtarget
effect
gener
esirna
strongli
inhibit
hbv
gene
express
replic
may
advantag
hbv
strain
variabl
genet
hepat
b
viru
hbv
caus
acut
chronic
infect
human
although
effect
vaccin
avail
prevent
transmiss
hbv
hbv
infect
remain
global
health
problem
due
million
chronic
hbvinfect
peopl
worldwid
individu
rel
high
risk
develop
endstag
liver
diseas
liver
cirrhosi
hepatocellular
carcinoma
seeger
mason
date
treatment
regiment
chronic
hepat
b
costli
limit
effect
onethird
patient
treat
alphainterferon
show
sustain
respons
nucleosid
analogu
elimin
viru
complet
may
select
resist
viral
variant
marcellin
thu
urgent
develop
new
antivir
drug
hbv
rna
interfer
rnai
process
wherebi
doublestrand
rna
dsrna
induc
sequencespecif
degrad
homolog
messeng
rna
mrna
hannon
process
mediat
small
interf
rna
sirna
length
nucleotid
natur
rnai
pathway
sirna
deriv
process
long
dsrna
nucleas
dicer
discret
use
chemic
synthes
vectorexpress
sirna
mani
clinic
import
virus
includ
human
immunodefici
viru
hiv
sever
acut
respiratori
syndrom
coronaviru
hbv
hepat
c
viru
hcv
could
inhibit
vitro
haasnoot
et
al
li
et
al
randal
rice
stevenson
wu
nandamuri
number
recent
studi
demonstr
hbv
gene
express
viral
replic
could
inhibit
giladi
et
al
guo
et
al
hamasaki
et
al
klein
et
al
konishi
et
al
mccaffrey
et
al
morrissey
et
al
b
shlomai
shaul
wu
et
al
even
clear
liver
transgen
mice
sirna
synthes
chemic
vectorexpress
uprichard
et
al
studi
sirna
target
differ
region
hbv
genom
use
genet
variat
viral
genom
may
lead
escap
silenc
effect
report
polioviru
gitlin
et
al
boden
et
al
da
et
al
hcv
wilson
richardson
problem
could
overcom
target
altern
site
viral
genom
shown
hcv
wilson
richardson
due
genet
variabl
hbv
treatment
sirna
face
problem
natur
occur
treatmentinduc
nucleotid
substitut
hbv
genom
thu
gene
silenc
strategi
target
multipl
site
warrant
yang
et
al
show
escherichia
coli
rnase
iii
digest
dsrna
effici
short
piec
end
structur
sirna
endoribonucleaseprepar
sirna
esirna
abl
target
multipl
site
within
mrna
verifi
silenc
target
mrna
effici
specif
calegari
et
al
kittler
et
al
yang
et
al
h
yang
et
al
zhu
jiang
present
studi
abil
esirna
inhibit
hbv
gene
express
replic
investig
esirna
target
hbv
c
gene
prepar
vitro
transcript
rnase
iii
digest
inhibit
hbv
gene
express
replic
esirna
demonstr
transient
cotransfect
experi
cell
line
stabli
integr
hbv
genom
effect
esirna
target
hbv
gene
compar
chemic
synthet
sirna
code
region
hbsag
nt
hbcag
nt
amplifi
hbv
genom
subtyp
ayw
genbank
access
clone
vector
invitrogen
karlsruh
de
primer
hcnco
use
pcr
amplif
list
tabl
clone
insert
orient
regard
promot
select
sequenc
verifi
construct
correct
esirna
target
code
region
hbsag
hbcag
sesirna
cesirna
prepar
use
silenc
sirna
cocktail
kit
rnase
iii
ambion
darmstadt
de
accord
manufactur
instruct
briefli
singl
strand
rna
transcrib
plasmid
use
polymeras
anneal
form
doubl
strand
rna
esirna
gener
final
digest
purifi
dsrna
rnase
iii
c
h
verifi
gel
electrophoresi
agaros
gel
plasmid
contain
hcv
core
region
nt
lu
et
al
use
prepar
hcvesirna
scrambl
esirna
control
sequenc
sirna
target
code
region
antigen
hbv
adw
strain
design
use
onlin
softwar
ambion
wwwambioncom
combin
algorithm
describ
reynold
et
al
sequenc
sirna
gaa
tcc
tca
caa
tac
cgc
nt
ggt
atg
ttg
ccc
gtt
tgt
nt
gga
acc
tct
atg
tat
ccc
nt
sirna
green
fluoresc
protein
sigfp
cgg
caa
gct
gac
cct
gaa
use
control
sirna
purchas
qiagen
bhk
cell
cell
cell
provid
prof
g
arc
hbv
serotyp
ayw
genotyp
genbank
access
sell
et
al
maintain
eagl
minim
essenti
medium
rpmi
medium
respect
supplement
fetal
bovin
serum
uml
penicillin
gml
streptomycin
cell
seed
chamber
slide
plate
confluenc
h
cell
transfect
lipofectamin
invitrogen
karlsruh
de
follow
manufactur
instruct
g
g
plasmid
dna
l
l
lipofectamin
place
well
chamber
slide
plate
respect
replicationcompet
hbv
construct
wta
gener
insert
full
length
wild
type
hbv
genom
kindli
provid
prof
han
genotyp
subtyp
ayw
genbank
access
vector
h
yang
et
al
vector
contain
cytomegaloviru
cmv
promot
upstream
short
recombin
hbv
sequenc
allow
infram
insert
full
length
hbv
genom
follow
sapi
digest
cmv
promot
upstream
precor
initi
site
allow
effici
transcript
pregenom
rna
follow
transfect
liver
cell
line
two
vector
phbeex
phbcex
construct
express
hbeag
hbcag
respect
region
hbv
genom
nt
nt
amplifi
primer
respect
tabl
digest
ecorv
xhoi
insert
vector
via
ecorv
xhoi
site
express
plasmid
encod
hbsag
genotyp
subtyp
ayw
genotyp
c
subtyp
adr
genotyp
subtyp
adw
describ
ireland
et
al
level
hbsag
hbeag
cell
supernat
determin
use
architect
system
hbsag
hbeag
cmia
kit
abbott
laboratori
wiesbadendelkenheim
de
accord
manufactur
instruct
hepat
b
core
antigen
visual
stain
specif
antibodi
transfect
cell
cultur
h
fix
methanol
phosphatebuff
salin
pb
stain
polyclon
rabbit
antihbc
antibodi
dako
hamburg
de
goat
antirabbit
immunoglobulin
gfluorescein
isothiocyan
sigma
munich
de
use
secondari
antibodi
experi
stain
visual
fluoresc
microscop
nikon
tokyo
jp
excit
wavelength
nm
total
rna
extract
transfect
cell
trizol
reagent
invitrogen
karlsruh
de
accord
manufactur
instruct
northern
blot
analysi
carri
agaroseformaldehyd
method
briefli
g
total
rna
per
sampl
separ
agaroseformaldehyd
gel
blot
hybondn
nylon
membran
amersham
buckinghamshir
gb
hbv
transcript
detect
use
plabel
full
length
hbv
probe
hybrid
signal
visual
analyz
phosphoimag
cyclon
parkard
instrument
hbv
replic
intermedi
purifi
intracellular
core
particl
accord
method
describ
sterneck
et
al
minor
modif
briefli
cell
wash
icecold
pb
lyse
ml
lysi
buffer
contain
mm
trishcl
ph
mm
edta
c
min
nuclei
pellet
centrifug
supernat
adjust
mm
mgcl
treat
gml
dnase
roch
mannheim
de
c
min
reaction
stop
addit
edta
final
concentr
mm
protein
digest
mgml
proteinas
k
qiagen
de
sodium
dodecyl
sulfat
c
h
hbv
nucleocapsidassoci
dna
purifi
phenolchloroform
extract
follow
isopropanol
precipit
ad
g
trna
volum
sodium
acet
ph
isol
hbv
dna
subject
agaros
gel
electrophoresi
follow
denatur
southern
blot
hbv
dna
detect
hybrid
plabel
full
length
hbv
probe
hybrid
signal
visual
analyz
phosphoimag
cyclon
parkard
instrument
two
microgram
total
rna
per
sampl
revers
transcrib
use
moloney
murin
leukemia
viru
revers
transcriptas
mmlv
rt
promega
mannheim
de
oligo
dt
invitrogen
karlsruh
de
primer
cdna
fragment
amplifi
use
primer
list
tabl
cycl
paramet
cycl
c
min
ii
cycl
c
c
c
iii
cycl
c
min
pcr
product
subject
agaros
gel
electrophoresi
visual
ethidium
bromid
stain
quantit
pcr
carri
use
platinum
sybr
green
qpcr
supermix
udg
invitrogen
karlsruh
de
roch
lightcycl
pcr
perform
follow
cycl
paramet
cycl
c
c
c
specif
pcr
product
verifi
melt
curv
analysi
agaros
gel
electrophoresi
examin
inhibitori
effect
esirna
hbv
gene
express
express
plasmid
encod
hbsag
hbeag
cotransfect
esirna
cell
express
level
hbsag
hbeag
cell
cultur
supernat
determin
h
later
cmia
cotransfect
sesirna
cesirna
concentr
nm
reduc
express
level
hbsag
hbeag
control
without
transfect
esirna
respect
fig
b
inhibit
hbcag
express
cesirna
verifi
stain
cell
transfect
hbcag
express
plasmid
without
cesirna
fig
hbcag
express
transfect
cell
strongli
reduc
cesirna
determin
whether
esirna
abl
inhibit
hbv
replic
cell
transfect
wta
presenc
sesirna
cesirna
express
hbsag
hbeag
cell
cultur
supernat
reduc
significantli
esirna
fig
decreas
hbsag
level
supernat
measur
cotransfect
sesirna
cesirna
respect
likewis
sesirna
cesirna
suppress
express
level
hbeag
control
respect
fig
amount
hbv
replic
intermedi
reduc
cell
esirna
dosedepend
manner
fig
hbv
replic
intermedi
detect
cell
treat
nm
sesirna
cesirna
northern
blot
analysi
show
hbv
transcript
reduc
level
control
fig
sesirna
cesirna
examin
cell
stabli
integr
hbv
dimer
cell
line
produc
hbv
rna
replic
intermedi
stabl
level
cell
transfect
nm
nm
sesirna
cesirna
incub
h
treatment
esirna
reduc
hbsag
concentr
cultur
supernat
fig
hbeag
concentr
cultur
supernat
chang
transfect
sesirna
cesirna
effect
suppress
hbeag
level
hbv
replic
intermedi
reduc
control
sesirna
cesirna
concentr
nm
respect
fig
similarli
level
hbv
transcript
decreas
control
thu
silenc
hbv
transcript
cell
transfect
stabli
singl
transfect
esirna
limit
effect
number
specif
sirna
shown
knock
correspond
hbv
transcript
effici
vitro
vivo
therefor
abil
esirna
synthet
sirna
inhibit
hbv
gene
express
viral
replic
compar
three
synthet
sirna
target
code
region
hbsag
inhibit
hbsag
express
differ
effect
fig
howev
silenc
hbsag
express
synthet
sirna
impair
strongli
nucleotid
variat
fig
g
substitut
posit
target
sequenc
reduc
abil
inhibit
express
hbsag
similarli
two
nucleotid
substitut
target
sequenc
abolish
silenc
effect
complet
contrast
mutat
affect
silenc
effect
sesirna
data
shown
see
abil
sesirna
inhibit
hbv
gene
express
replic
compar
cell
cotransfect
wta
nm
sesirna
nm
product
hbsag
hbeag
suppress
strongli
sesirna
fig
level
hbv
replic
intermedi
reduc
control
seirna
vs
fig
led
signific
decreas
amount
hbv
transcript
control
fig
therefor
synthet
sirna
may
effici
gene
silenc
esirna
present
use
synthet
sirna
suggest
esirna
direct
multipl
site
target
sequenc
therefor
abil
sesirna
inhibit
express
heterolog
hbsag
sequenc
examin
three
hbsag
express
plasmid
encod
differ
hbsag
genosubtyp
cotransfect
sesirna
determin
hbsag
express
level
supernat
show
cotransfect
sesirna
reduc
equal
express
hbsag
regardless
subtyp
fig
larg
dsrna
length
bp
might
induc
interferon
respons
cell
thu
necessari
examin
whether
use
esirna
induc
isg
cell
exclud
offtarget
effect
rtpcr
analysi
carri
monitor
induct
cell
express
cell
increas
treatment
unit
transfect
cell
sesirna
cesirna
increas
express
fig
thu
esirna
abl
activ
interferon
respons
hepatoma
cell
studi
abil
specif
esirna
silenc
hbv
gene
express
replic
examin
detail
esirna
direct
code
sequenc
hbsag
hbcag
capabl
inhibit
hbv
gene
express
viral
replic
transient
cotransfect
system
cell
inhibit
effect
specif
dosedepend
theoret
esirna
target
hbsag
effect
counterpart
target
hbcag
sinc
hbv
region
share
major
viral
transcript
rna
speci
suppress
sesirna
howev
cesirna
effect
even
effect
sesirna
cesirna
inhibit
hbsag
express
like
act
indirectli
reduct
hbv
replic
unknown
mechan
interestingli
sesirna
cesirna
effect
inhibit
hbv
replic
cell
hbeag
express
reduc
cesirna
one
explan
small
amount
hbsag
transcript
need
synthesi
hbsag
data
demonstr
advantag
use
esirna
genet
heterogen
target
sequenc
abil
use
sirna
target
simultan
differ
region
viral
genom
may
increas
effici
treatment
addit
prevent
appear
resist
mutant
eight
genotyp
ah
hbv
distinguish
genotyp
differ
other
nucleotid
level
phylogenet
analysi
shown
eight
genotyp
subdivid
genotyp
subtyp
schaefer
difficult
identifi
highli
effect
sirna
target
conserv
nt
sequenc
genotyp
genotyp
subtyp
esirna
gener
long
dsrna
mixtur
sirna
divers
specif
would
abl
target
whole
mrna
sequenc
retain
abil
gene
silenc
result
current
studi
show
esirna
gener
hbv
subtyp
ayw
applic
differ
hbsag
subtyp
test
contrast
singl
nucleotid
mutat
target
sequenc
abrog
silenc
effect
chemic
synthet
sirna
similarli
weinberg
et
al
use
vector
produc
dicer
substrat
could
gener
multipl
sirna
approach
would
advantag
limit
escap
target
rang
sequenc
found
differ
viral
genotyp
quasispeci
sirnaspecif
featur
low
gc
content
bia
toward
low
intern
stabil
sens
strand
terminu
lack
invert
repeat
sens
strand
base
prefer
like
contribut
effici
rnai
process
reynold
et
al
accord
criteria
would
limit
number
option
sequenc
rnai
target
given
mrna
process
long
dsrna
gener
varieti
small
dsrna
molecul
differ
degre
rna
interfer
thu
understand
esirna
would
less
effect
comparison
defin
optim
synthet
sirna
within
rang
use
concentr
howev
synthet
sirna
may
differ
abil
gene
silenc
thu
may
less
effici
esirna
xuan
et
al
recent
sever
vivo
studi
base
use
cation
liposom
polyplex
chemic
modifi
sirna
show
improv
effect
sirna
aigner
morrissey
et
al
b
use
liverspecif
apo
aimedi
sirna
deliveri
method
kim
et
al
show
administr
synthet
sirna
reduc
significantli
hbv
protein
express
advantag
effect
low
dose
longterm
effect
uniqu
approach
sirna
deliveri
creat
foundat
develop
new
class
promis
therapeut
method
hepat
virus
vivo
use
esirna
need
investig
use
liverspecif
sirna
deliveri
method
